低剂量阿司匹林每日一次在全关节置换术后静脉血栓栓塞预防中非劣效
该回顾性研究分析2014至2023年单中心8,073例初次全髋和全膝关节置换术患者,比较每日一次81mg阿司匹林与更高剂量/频率阿司匹林或更强抗凝药的90天静脉血栓栓塞(VTE)发生率。总体VTE率为1.1%,全髋低于全膝(0.9%对1.4%,P=0.02),各抗凝方法间VTE率无差异(P=0.61),仅Elixhauser合并症指数较高预测VTE(OR 1.09,95%CI 1.04-1.15,P<0.01)。结论认为每日一次81mg阿司匹林方案VTE发生率可接受,非劣效于常规每日两次81mg或更高剂量及强效抗凝药。
要点
- 每日一次81mg阿司匹林预防全关节置换术后VTE,发生率可接受且非劣效于更强方案。
- 总体VTE率1.1%,全髋置换低于全膝置换(0.9%对1.4%,P=0.02)。
- 仅Elixhauser合并症指数较高预测VTE(OR 1.09,95%CI 1.04-1.15,P<0.01)。
核心结论
- 每日一次81mg阿司匹林方案在全关节置换术后VTE预防中非劣效于每日两次81mg或更高剂量阿司匹林及强效抗凝药。
研究设计与样本
- 回顾性研究,纳入2014至2023年单中心8,073例初次全髋和全膝关节置换术患者。
- 通过全州登记系统识别术后90天内VTE事件,比较不同抗凝方案的VTE率。
- 采用单因素和逻辑回归分析。
主要发现
- 总体VTE率为1.1%(90/8,073)。
- 全髋置换术后VTE发生率低于全膝置换(0.9%对1.4%,P=0.02)。
- 逻辑回归分析显示各抗凝方法间VTE率无差异(P=0.61)。
- 仅Elixhauser合并症指数较高预测VTE(OR 1.09,95%CI 1.04-1.15,P<0.01)。
关键数值与推荐
- 每日一次81mg阿司匹林为机构方案,VTE发生率可接受且非劣效于每日两次81mg或更高剂量及强效抗凝药。
临床怎么用
- 全关节置换术后可考虑每日一次81mg阿司匹林进行VTE预防,尤其适用于合并症较少患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is a well-known complication after primary total joint arthroplasty (TJA). Aspirin is increasingly used for VTE prophylaxis after total hip arthroplasty and total knee arthroplasty given its efficacy and favorable side effect profile, although optimal dosing and frequency remain uncertain. Given the long-term effect of aspirin on platelet function, the conventional twice-daily frequency (or higher dosing) of aspirin may be unnecessary. The purpose of this study was to investigate the VTE incidence in patients receiving 81 mg aspirin once daily for prophylaxis after primary TJA, which has been our institution's protocol for the past decade. METHODS: This was a retrospective study of 8,073 patients who underwent primary THA and TKA from a single institution between 2014 and 2023. Patients who experienced a VTE event within 90 days of surgery were identified using our statewide registry. The VTE rates were compared between patients receiving aspirin 81 mg once daily, a higher dose/frequency of aspirin, or more potent anticoagulation. Univariate and logistic regression analyses were performed. RESULTS: The overall VTE rate was 1.1% (90 of 8,073), with a lower incidence after total hip arthroplasty compared to total knee arthroplasty (0.9 versus 1.4%, respectively, P = 0.02). In our logistic regression analyses, there was no difference in VTE rate between all anticoagulation methods (P = 0.61). The only variable that was predictive of VTE was a higher Elixhauser Comorbidity Index (odds ratio 1.09, 95% confidence interval 1.04 to 1.15, P < 0.01). CONCLUSIONS: Our institutional protocol of using 81 mg aspirin once daily has an acceptable incidence rate of VTE after TJA. It is noninferior to the conventional twice-daily 81 mg aspirin or higher dosing, as well as potent anticoagulants.
引用
- Guo EW, Honey NE, Wang Z, et al. Low-Dose Aspirin Once Daily Is Noninferior for Venous Thromboembolic Prophylaxis After Primary Total Joint Arthroplasty: An Analysis of 8,073 Cases Over 10 Years. J Arthroplasty. 2026. PMID: 42456789. doi:10.1016/j.arth.2026.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。